Arthur Jeng
Infectious Disease · Sylmar, CANPI 1013070499
Payments from drug & device makers
Across 1,205 payments — averaging $802.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$171K
- Pfizer$148K
- Astellas Pharma Global Development$127K
- Merck$94K
- Astellas Pharma US Inc$82K
- Biofire Diagnostics, LLC$81K
- plus $263K from 10 others
Across 3 payments — averaging $872.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomerieux Inc$2K
- Biofire Diagnostics, LLC$625
What the payments were for
- Consulting fees$29,0024%
- Speaking & faculty fees$625,99282%
- Travel & lodging$80,80811%
- Food & beverage$27,8074%
- Education$2,0460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 215 | $171,122 |
| Pfizer(2 entities) | 212 | $148,411 |
| Astellas Pharma Global Development | 4 | $127,168 |
| Merck | 123 | $93,872 |
| Astellas Pharma US Inc | 162 | $82,499 |
| Biofire Diagnostics, LLC | 11 | $80,836 |
| Ferring Pharmaceuticals Inc. | 163 | $64,337 |
| Melinta Therapeutics, LLC | 102 | $63,947 |
| La Jolla Pharmaceutical Company | 46 | $26,017 |
| Biomerieux Inc | 10 | $23,059 |
| Tetraphase Pharmaceuticals, Inc. | 27 | $22,513 |
| Paratek Pharmaceuticals, Inc. | 45 | $21,621 |
| Amgen | 40 | $18,150 |
| Dynavax Technologies Corporation | 18 | $17,612 |
| AbbVie(2 entities) | 26 | $6,145 |
| Gilead | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$149,688
- ZERBAXA$78,741
- CRESEMBA$72,600
- ABRYSVO$55,490
- REBYOTA$49,970
- Xerava$33,974
- PREVNAR 20$32,917
- Kimyrsa$32,812
- Vabomere$27,392
- NUZYRA$20,896
- Enbrel$17,576
- Heplisav-B$17,198
- FilmArray BCID Panel$14,233
- PREVNAR - 13$13,067
- BPN14770$10,620
- COMIRNATY$10,306
- PENBRAYA$10,246
- Zevtera$10,109
- FILMARRAY PNEUMONIA PANEL (PNEUMO)$8,715
- RECARBRIO$6,690
How this compares
$967,332 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $60,446 |
| JulucaDolutegravir/Rilpivirine | 14 | $44,641 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $505 |
| Gabapentin | 16 | $81 |
| Tamsulosin Hcl | 13 | $59 |
| Latanoprost | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $24 | $60,44615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in Sylmar
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- James McKinnellTorrance$4.3M
- Loren MillerTorrance$4.1M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.